Growth Metrics

Definium Therapeutics (DFTX) Return on Invested Capital (2022)

Definium Therapeutics (DFTX) reported Return on Invested Capital of 0.0% for Q3 2022, little changed on a QoQ basis from 0.0% in Q2 2022.

Definium Therapeutics (DFTX) has 1 years of Return on Invested Capital data on file, last reported at 0.0% in Q3 2022.

  • Quarterly Return on Invested Capital changed N/A year-over-year to 0.0% in Q3 2022, while the trailing twelve-month figure through Sep 2022 was 0.0% (changed N/A YoY) and the FY2021 annual result came in at 0.0%, changed N/A from the prior year.
  • Return on Invested Capital steadied at 0.0% in Q3 2022 per DFTX's latest filing, from 0.0% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.0% in Q2 2022 and bottomed at 0.0% in Q3 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROIC (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -0.01%
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 0.00%
7 Evaxion A 64.16 Bn 64.14 Bn - -0.01%
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 0.00%
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 0.01%
10 Definium Therapeutics 2.42 Bn 2.06 Bn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2022 0.00%
Jun 30, 2022 0.00%